Miyagawa, Ippei
Nakano, Kazuhisa
Iwata, Shigeru
Nakayamada, Shingo
Saito, Kazuyoshi
Hanami, Kentaro
Fukuyo, Shunsuke
Kubo, Satoshi
Kawabe, Akio
Miyazaki, Yusuke
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Article History
Received: 25 January 2019
Accepted: 6 June 2019
First Online: 22 June 2019
Ethics approval and consent to participate
: Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee following the Helsinki Declaration. This retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived.
: Not applicable.
: Y. Tanaka has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers, Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, and Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, and Taisho-Toyama.K. Nakano has received speaking fees from Astellas, UCB, Mitsubishi-Tanabe, and Eisai and has received research grants from Mitsubishi-Tanabe, Eisai, and Eli Lilly.S. Nakayamada received speaking fees and/or honoraria from Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei, and Pfizer (less than $10,000 each) and also research grants from Mitsubishi-Tanabe, Takeda, Novartis, and MSD.